Economic compensation interventions to increase uptake of voluntary medical male circumcision for HIV prevention: A systematic review and meta-analysis
Caitlin E. Kennedy aff001; Ping Teresa Yeh aff001; Kaitlyn Atkins aff001; Virginia A. Fonner aff002; Michael D. Sweat aff002; Kevin R. O’Reilly aff002; George W. Rutherford aff003; Rachel Baggaley aff004; Julia Samuelson aff004
Působiště autorů: Social and Behavioral Interventions Program, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America aff001; Division of Global and Community Health, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, United States of America aff002; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America aff003; Department of HIV, World Health Organization, Geneva, Switzerland aff004
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
Economic compensation interventions may help support higher voluntary medical male circumcision (VMMC) coverage in priority sub-Saharan African countries. To inform World Health Organization guidelines, we conducted a systematic review of economic compensation interventions to increase VMMC uptake.
Economic compensation interventions were defined as providing money or in-kind compensation, reimbursement for associated costs (e.g. travel, lost wages), or lottery entry. We searched five electronic databases and four scientific conferences for studies examining the impact of such interventions on VMMC uptake, HIV testing and safer-sex/risk-reduction counseling uptake within VMMC, community expectations about compensation, and potential coercion. We screened citations, extracted data, and assessed risk of bias in duplicate. We conducted random-effects meta-analysis. We also reviewed studies examining acceptability, values/preferences, costs, and feasibility.
Of 2484 citations identified, five randomized controlled trials (RCTs) and three non-randomized controlled trials met our eligibility criteria. Studies took place in Kenya, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. Meta-analysis of four RCTs showed significant impact of any economic compensation on VMMC uptake (relative risk: 5.23, 95% CI: 3.13 to 8.76). RCTs of food/transport vouchers and conditional cash transfers generally showed increases in VMMC uptake, but lotteries, subsidized VMMC, and receiving a gift appeared somewhat less effective. Three non-randomized trials showed mixed impact. Six additional studies suggested economic compensation interventions were generally acceptable, valued for addressing key barriers, and motivating to men. However, some participants felt they were insufficiently motivating or necessary; one study suggested they might raise community suspicions. One study from South Africa found a program cost of US$91 per additional circumcision and US$450-$1350 per HIV infection averted.
Economic compensation interventions, particularly transport/food vouchers, positively impacted VMMC uptake among adult men and were generally acceptable to potential clients. Carefully selected economic interventions may be a useful targeted strategy to enhance VMMC coverage.
Circumcision – Database searching – Health economics – HIV – HIV prevention – Metaanalysis – Randomized controlled trials – Salaries
1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Medicine. 2005;2(2):1549–676.
2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;(369):1474–547X.
3. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;(369):1474–547X.
4. WHO. WHO progress brief: voluntary medical male circumcision for HIV prevention. Geneva, Switzerland: World Health Organization, 2018.
5. Mills EJ, Beyrer C, Birungi J, Dybul MR. Engaging men in prevention and care for HIV/AIDS in Africa. PLoS Medicine. 2012;9(2):e1001167. doi: 10.1371/journal.pmed.1001167 22346735
6. Carrasco MA, Wilkinson J, Kasdan B, Fleming P. Systematic review of barriers and facilitators to voluntary medical male circumcision in priority countries and programmatic implications for service uptake. Global Public Health. 2019;14(1):1744–06.
7. UNAIDS. Communities at the Centre: UNAIDS Global AIDS Update 2019. Durham, NC: FHI360, WHO, UNAIDS & AVAC, 2019.
8. UNAIDS, WHO. A framework for voluntary medical male circumcision: Effective HIV prevention and a gateway to improved adolescent boys’ & men’s health in eastern and southern Africa by 2021—policy brief. 2016.
9. Carrasco MA, Grund JM, Davis SM, Ridzon R, Mattingly M, Wilkinson J, et al. Systematic review of the effect of economic compensation and incentives on uptake of voluntary medical male circumcision among men in sub-Saharan Africa. AIDS Care. 2018;30(9):1071–82. doi: 10.1080/09540121.2018.1453921 29566546
10. Choko AT, Candfield S, Maheswaran H, Lepine A, Corbett EL, Fielding K. The effect of demand-side financial incentives for increasing linkage into HIV treatment and voluntary medical male circumcision: a systematic review and meta-analysis of randomised controlled trials in low- and middle-income countries. PloS One. 2018;13(11):e0207263. doi: 10.1371/journal.pone.0207263 30427889
11. Ensor S, Davies B, Rai T, Ward H. The effectiveness of demand creation interventions for voluntary male medical circumcision for HIV prevention in sub-Saharan Africa: a mixed methods systematic review. Journal of the International AIDS Society. 2019;22 Suppl 4:e25299.
12. Galarraga O, Genberg BL, Martin RA, Barton Laws M, Wilson IB. Conditional economic incentives to improve HIV treatment adherence: literature review and theoretical considerations. AIDS and Behavior. 2013;17(7):2283–92. doi: 10.1007/s10461-013-0415-2 23370833
13. Operario D, Kuo C, Sosa-Rubi SG, Galarraga O. Conditional economic incentives for reducing HIV risk behaviors: integration of psychology and behavioral economics. Health Psychology. 2013;32(9):932–40. doi: 10.1037/a0032760 24001243
14. Swann M. Economic strengthening for HIV testing and linkage to care: a review of the evidence. AIDS Care. 2018;30 Suppl 3:85–98.
15. Bassett IV, Wilson D, Taaffe J, Freedberg KA. Financial incentives to improve progression through the HIV treatment cascade. Current Opinion in HIV and AIDS. 2015;10(6):451–63. doi: 10.1097/COH.0000000000000196 26371461
16. Haberer JE, Sabin L, Amico KR, Orrell C, Galarraga O, Tsai AC, et al. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. Journal of the International AIDS Society. 2017;20(1):21371. doi: 10.7448/IAS.20.1.21371 28630651
17. Gopalan SS, Mutasa R, Friedman J, Das A. Health sector demand-side financial incentives in low- and middle-income countries: a systematic review on demand- and supply-side effects. Social Science & Medicine (1982). 2014;100:72–83.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.
19. O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. Journal of Clinical Epidemiology. 2014;67(1):56–64. doi: 10.1016/j.jclinepi.2013.08.005 24189091
20. Djimeu EW, Brown AN. Strength of evidence on demand creation for voluntary medical male circumcision from 7 impact evaluations in southern and eastern Africa. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S321–S5.
21. Higgins JPT, Savovic J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 6-1-0 [updated 2019]. London, England: The Cochrane Collaboration; 2019.
22. Kennedy CE, Fonner VA, Armstrong KA, Denison JA, Yeh PT, O'Reilly KR, et al. The Evidence Project risk of bias tool: assessing study rigor for both randomized and non-randomized intervention studies. Systematic Reviews. 2019;8(1):3. doi: 10.1186/s13643-018-0925-0 30606262
23. WHO. WHO handbook for guideline development. Geneva, Switzerland: World Health Organization; 2012.
24. Bazant E, Mahler H, Machaku M, Lemwayi R, Kulindwa Y, Lija JG, et al. A randomized evaluation of a demand creation lottery for voluntary medical male circumcision among adults in Tanzania. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S285–S92.
25. Kaufman ZA, DeCelles J, Bhauti K, Hershow RB, Weiss HA, Chaibva C, et al. A sport-based intervention to increase uptake of voluntary medical male circumcision among adolescent male Sstudents: results from the MCUTS 2 cluster-randomized trial in Bulawayo, Zimbabwe. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S292–8.
26. Semeere AS, Castelnuovo B, Bbaale DS, Kiragga AN, Kigozi J, Muganzi AM, et al. Innovative demand creation for voluntary medical male circumcision targeting a high impact male population: a pilot study engaging pregnant women at antenatal clinics in Kampala, Uganda. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S273–9.
27. Thirumurthy H, Masters SH, Rao S, Bronson MA, Lanham M, Omanga E, et al. Effect of providing conditional economic compensation on uptake of voluntary medical male circumcision in Kenya: a randomized clinical trial. JAMA. 2014;312(7):703–11. doi: 10.1001/jama.2014.9087 25042290
28. Thirumurthy H, Masters SH, Rao S, Murray K, Prasad R, Zivin JG, et al. The effects of providing fixed compensation and lottery-based rewards on uptake of medical male circumcision in Kenya: a randomized trial. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S299–305.
29. Thornton R, Godlonton S. Medical male circumcision: How does price affect the risk-profile of take-up? Preventive Medicine. 2016;92:68–73. doi: 10.1016/j.ypmed.2016.06.003 27283093
30. Wilson N, Frade S, Rech D, Friedman W. Advertising for demand creation for voluntary medical male circumcision. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S288–91.
31. Zanolini A, Bolton C, Lyabola LL, Phiri G, Samona A, Kaonga A, et al. Feasibility and effectiveness of a peer referral incentive intervention to promote male circumcision uptake in Zambia. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S257–63.
32. Chinkhumba J, Godlonton S, Thornton R. The demand for medical male circumcision. American Economic Journal: Applied Economics. 2014;6(2):152–77.
33. DeCelles J, Hershow RB, Kaufman ZA, Gannett KR, Kombandeya T, Chaibva C, et al. Process evaluation of a sport-based voluntary medical male circumcision demand-creation intervention in Bulawayo, Zimbabwe. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S304–S8.
34. Evens E, Lanham M, Hart C, Loolpapit M, Oguma I, Obiero W. Identifying and addressing barriers to uptake of voluntary medical male circumcision in Nyanza, Kenya among men 18–35: a qualitative study. PloS One. 2014;9(6):e98221. doi: 10.1371/journal.pone.0098221 24901226
35. Evens E, Lanham M, Murray K, Rao S, Agot K, Omanga E, et al. Use of economic compensation to increase demand for voluntary medical male circumcision in Kenya: Qualitative interviews with male participants in a randomized controlled trial and their partners. Journal of Acquired Immune Deficiency Syndromes. 2016;72 Suppl 4:S316–S20.
36. Marshall E, Rain-Taljaard R, Tsepe M, Monkwe C, Taljaard D, Hlatswayo F, et al. Obtaining a male circumcision prevalence rate of 80% among adults in a short time: An observational prospective intervention study in the Orange Farm township of South Africa. Medicine. 2017;96(4):e5328. doi: 10.1097/MD.0000000000005328 28121914
37. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011;25(14):1753–60. doi: 10.1097/QAD.0b013e3283463eec 21412127
Článek vyšel v časopise
2020 Číslo 1
- Nový typ fixace umožňuje pravidelnou hygienu končetiny i pobyt ve vodě
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Není statin jako statin aneb praktický přehled rozdílů jednotlivých molekul
- Nedostatek hořčíku se projevuje u stále více lidí
- Pregabalin je účinné léčivo s příznivým bezpečnostním profilem pro pacienty s neuropatickou bolestí